Literature DB >> 28104717

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Shakti H Ramkissoon1, Pratiti Bandopadhayay1, Jaeho Hwang1, Lori A Ramkissoon1, Noah F Greenwald1, Steven E Schumacher1, Ryan O'Rourke1, Nathan Pinches1, Patricia Ho1, Hayley Malkin1, Claire Sinai1, Mariella Filbin1, Ashley Plant1, Wenya Linda Bi1, Michael S Chang1, Edward Yang1, Karen D Wright1, Peter E Manley1, Matthew Ducar1, Sanda Alexandrescu1, Hart Lidov1, Ivana Delalle1, Liliana C Goumnerova1, Alanna J Church1, Katherine A Janeway1, Marian H Harris1, Laura E MacConaill1, Rebecca D Folkerth1, Neal I Lindeman1, Charles D Stiles1, Mark W Kieran1, Azra H Ligon1, Sandro Santagata1, Adrian M Dubuc1, Susan N Chi1, Rameen Beroukhim1, Keith L Ligon1.   

Abstract

BACKGROUND: Clinical genomics platforms are needed to identify targetable alterations, but implementation of these technologies and best practices in routine clinical pediatric oncology practice are not yet well established.
METHODS: Profile is an institution-wide prospective clinical research initiative that uses targeted sequencing to identify targetable alterations in tumors. OncoPanel, a multiplexed targeted exome-sequencing platform that includes 300 cancer-causing genes, was used to assess single nucleotide variants and rearrangements/indels. Alterations were annotated (Tiers 1-4) based on clinical significance, with Tier 1 alterations having well-established clinical utility. OncoCopy, a clinical genome-wide array comparative genomic hybridization (aCGH) assay, was also performed to evaluate copy number alterations and better define rearrangement breakpoints.
RESULTS: Cancer genomes of 203 pediatric brain tumors were profiled across histological subtypes, including 117 samples analyzed by OncoPanel, 146 by OncoCopy, and 60 tumors subjected to both methodologies. OncoPanel revealed clinically relevant alterations in 56% of patients (44 cancer mutations and 20 rearrangements), including BRAF alterations that directed the use of targeted inhibitors. Rearrangements in MYB-QKI, MYBL1, BRAF, and FGFR1 were also detected. Furthermore, while copy number profiles differed across histologies, the combined use of OncoPanel and OncoCopy identified subgroup-specific alterations in 89% (17/19) of medulloblastomas.
CONCLUSION: The combination of OncoPanel and OncoCopy multiplex genomic assays can identify critical diagnostic, prognostic, and treatment-relevant alterations and represents an effective precision medicine approach for clinical evaluation of pediatric brain tumors.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  array CGH; brain tumor; clinical sequencing; pediatric neuro-oncology; precision medicine

Mesh:

Year:  2017        PMID: 28104717      PMCID: PMC5570190          DOI: 10.1093/neuonc/now294

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  41 in total

1.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

2.  Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.

Authors:  Shakti H Ramkissoon; Wenya Linda Bi; Steven E Schumacher; Lori A Ramkissoon; Sam Haidar; David Knoff; Adrian Dubuc; Loreal Brown; Margot Burns; Jane B Cryan; Malak Abedalthagafi; Yun Jee Kang; Nikolaus Schultz; David A Reardon; Eudocia Q Lee; Mikael L Rinne; Andrew D Norden; Lakshmi Nayak; Sandra Ruland; Lisa M Doherty; Debra C LaFrankie; Margaret Horvath; Ayal A Aizer; Andrea Russo; Nils D Arvold; Elizabeth B Claus; Ossama Al-Mefty; Mark D Johnson; Alexandra J Golby; Ian F Dunn; E Antonio Chiocca; Lorenzo Trippa; Sandro Santagata; Rebecca D Folkerth; Philip Kantoff; Barrett J Rollins; Neal I Lindeman; Patrick Y Wen; Azra H Ligon; Rameen Beroukhim; Brian M Alexander; Keith L Ligon
Journal:  Neuro Oncol       Date:  2015-03-09       Impact factor: 12.300

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

5.  Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.

Authors:  Cláudia M Salgado; Dipanjan Basu; Marina Nikiforova; Ronald L Hamilton; Robin Gehris; Regina Jakacki; Ashok Panigrahy; Svetlana Yatsenko; Miguel Reyes-Múgica
Journal:  Melanoma Res       Date:  2015-10       Impact factor: 3.599

6.  Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

Authors:  Lori A Ramkissoon; Peleg M Horowitz; Justin M Craig; Shakti H Ramkissoon; Benjamin E Rich; Steven E Schumacher; Aaron McKenna; Michael S Lawrence; Guillaume Bergthold; Priscilla K Brastianos; Barbara Tabak; Matthew D Ducar; Paul Van Hummelen; Laura E MacConaill; Tina Pouissant-Young; Yoon-Jae Cho; Hala Taha; Madeha Mahmoud; Daniel C Bowers; Linda Margraf; Uri Tabori; Cynthia Hawkins; Roger J Packer; D Ashley Hill; Scott L Pomeroy; Charles G Eberhart; Ian F Dunn; Liliana Goumnerova; Gad Getz; Jennifer A Chan; Sandro Santagata; William C Hahn; Charles D Stiles; Azra H Ligon; Mark W Kieran; Rameen Beroukhim; Keith L Ligon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-30       Impact factor: 11.205

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

9.  DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.

Authors:  Justin M Craig; Natalie Vena; Shakti Ramkissoon; Ahmed Idbaih; Shaun D Fouse; Memet Ozek; Aydin Sav; D Ashley Hill; Linda R Margraf; Charles G Eberhart; Mark W Kieran; Andrew D Norden; Patrick Y Wen; Massimo Loda; Sandro Santagata; Keith L Ligon; Azra H Ligon
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

10.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

View more
  34 in total

1.  Prospective Clinical Sequencing of Adult Glioma.

Authors:  Siyuan Zheng; Kristin Alfaro-Munoz; Wei Wei; Xiaojing Wang; Fang Wang; Agda Karina Eterovic; Kenna R Mills Shaw; Funda Meric-Bernstam; Gregory N Fuller; Ken Chen; Roel G Verhaak; Gordon B Mills; W K Alfred Yung; Shiao-Pei Weathers; John F de Groot
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

Review 2.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

3.  Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors.

Authors:  Carl Koschmann; Yi-Mi Wu; Chandan Kumar-Sinha; Robert Lonigro; Pankaj Vats; Katayoon Kasaian; Marcin Cieslik; Xuhong Cao; Bailey Anderson; Kevin Frank; Lili Zhao; John R Prensner; Andrew H Zureick; Jessica Everett; Brendan Mullan; Bernard Marini; Sandra Camelo-Piragua; Sriram Venneti; Paul McKeever; Kathryn McFadden; Andrew P Lieberman; Marcia Leonard; Cormac O Maher; Hugh Garton; Karin Muraszko; Patricia Robertson; Dan Robinson; Arul M Chinnaiyan; Rajen Mody
Journal:  JCO Precis Oncol       Date:  2018-05-04

Review 4.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

5.  Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.

Authors:  Pedro Exman; Ana C Garrido-Castro; Melissa E Hughes; Rachel A Freedman; Tianyu Li; Lorenzo Trippa; Brittany L Bychkovsky; Romualdo Barroso-Sousa; Simona Di Lascio; Colin Mackichan; Max R Lloyd; Max Krevalin; Ethan Cerami; Margaret S Merrill; Rebecca Santiago; Lindsey Crowley; Nicole Kuhnly; Janet Files; Neal I Lindeman; Laura E MacConaill; Priti Kumari; Sara M Tolaney; Ian E Krop; Ron Bose; Bruce E Johnson; Cynthia X Ma; Deborah A Dillon; Eric P Winer; Nikhil Wagle; Nancy U Lin
Journal:  JCO Precis Oncol       Date:  2019-11-15

Review 6.  Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.

Authors:  Lori A Ramkissoon; Nicholas Britt; Alexander Guevara; Emily Whitt; Eric Severson; Pratheesh Sathyan; Laurie Gay; Julia Elvin; Jeffrey S Ross; Charlotte Brown; Kimberly Stogner-Underwood; Ryan Mott; David Kram; Roy Strowd; Glenn J Lesser; Shakti H Ramkissoon
Journal:  Curr Treat Options Oncol       Date:  2018-06-21

Review 7.  Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.

Authors:  Tej D Azad; Michael C Jin; Lydia J Bernhardt; Chetan Bettegowda
Journal:  Neurosurg Focus       Date:  2020-01-01       Impact factor: 4.047

8.  Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.

Authors:  Ashley S Plant; Shohei Koyama; Claire Sinai; Isaac H Solomon; Gabriel K Griffin; Keith L Ligon; Pratiti Bandopadhayay; Rebecca Betensky; Ryan Emerson; Glenn Dranoff; Mark W Kieran; Jerome Ritz
Journal:  J Neurooncol       Date:  2018-01-10       Impact factor: 4.130

9.  Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.

Authors:  Wenya Linda Bi; Lakshmi Nayak; David M Meredith; Joseph Driver; Ziming Du; Samantha Hoffman; Yvonne Li; Eudocia Quant Lee; Rameen Beroukhim; Mikael Rinne; Ricardo McFaline-Figueroa; Ugonma Chukwueke; Christine McCluskey; Sarah Gaffey; Andrew D Cherniack; Jennifer Stefanik; Lisa Doherty; Christina Taubert; Meghan Cifrino; Deborah LaFrankie; Thomas Graillon; Patrick Y Wen; Keith L Ligon; Ossama Al-Mefty; Raymond Y Huang; Alona Muzikansky; E Antonio Chiocca; Sandro Santagata; Ian F Dunn; David A Reardon
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 12.300

10.  Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification: a case report.

Authors:  Takeyoshi Tsutsui; Yoshiki Arakawa; Yasuhide Makino; Hiroharu Kataoka; Yohei Mineharu; Kentaro Naito; Sachiko Minamiguchi; Takanori Hirose; Sumihito Nobusawa; Yoshiko Nakano; Koichi Ichimura; Hironori Haga; Susumu Miyamoto
Journal:  Brain Tumor Pathol       Date:  2021-07-27       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.